期刊文献+

前列腺癌内分泌治疗现状 被引量:7

The status of endocrine therapy on prostate cancer
原文传递
导出
摘要 前列腺癌(prostatecancerPC)是欧美国家男性发病率最高的恶性肿瘤,近年来其在我国的发病率也逐年升高。雄激素在PC的发生、发展过程中扮演着重要的角色,所以内分泌治疗一直是前列腺癌研究领域的重点,但是其可能诱发激素非依赖型PC这也是临床医学面临的一大问题。本文就前列腺癌内分泌治疗的分类、作用机制、用药策略及临床效果等作一综述。 Prostate cancer(PC) is the most common malignancy of male in Europe and American.The incidence increased in recent years in our country.Steroid hormones play an important role in occurrence and development of prostate cancer,so endocrine therapy for prostate cancer has been the focus in this field.It may induce the hormone refractory prostate cancer,which is one of the major difficul-ties of clinical medicine.Classification,mechanism,administration strategy and clinical effects of endocrine therapy on prostate cancer are reviewed in this article.
出处 《现代生物医学进展》 CAS 2011年第2期371-374,共4页 Progress in Modern Biomedicine
关键词 前列腺癌 激素抵抗 激素依赖 内分泌治疗 prostate cancer hormone refractory hormone dependent endocrine therapy
  • 相关文献

参考文献28

  • 1Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology Recommendations for Initial Hormornal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer[J]. Clin Oncol, 2004, 22:2927-2941.
  • 2Oh WK. The evolving role of estrogen therapy in prostate cancer [J]. Ctin Prostate Cancer, 2002,1:81-89.
  • 3Agarwal DK, Costello AJ, Peters J, et al. Differential response of prostate specific antigen to testosterone surge after luteinizing hor- mone-releasing hormone analogue in prostate cancer and benign prostatic hypertrophy [J]. BJU Int, 2000, 85:690-695.
  • 4Seidenfeld J, Samson D J, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis[J]. Ann Intern Med, 2000, 132 (7):566-577.
  • 5Mcleod D, Zinner N, Tomera K, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer[J]. Urology, 2001, 58 (5):756-761.
  • 6Pavorte MM, de Voogt HJ, Viggiano G, et al. Comparison of diethyl- stilbestrol,cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: Final analysis of a ran- domized phase Ⅲ trial of the European Organization for Research on TreatmentofCaneerUrologcal Group[J]. J Uro1,1986, 136:624.
  • 7Thorpe SC, Azmatullah S, Fellows GJ, et al. A prospective,ran-domised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma [J]. Eur Urol, 1996, 29: 47.
  • 8Maximum androgen blockade in advanced prostate cancer:an overview of the random ised trials.Prostate Cancer Trialists' Collabo-rative Group[J]. Lancet, 2000, 355:1491-1498.
  • 9Labrie F, Candas B, Gomez JL, et al .Can combined and rogen block- ade provide long-term control or possible cure of localized prostate cancer? [J]. Urology, 2002, 60:115-119.
  • 10Klotz L, Schellhammer P, Carroll K A re-assessment of the role of combined and rogen blockade for advanced prostate cancer [J]. BJU Int, 2004,93:1 177-1182.

二级参考文献1

共引文献3

同被引文献68

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部